The Economic Weight of a Failed Screen
Screen failures are one of the most direct and underreported cost drivers in Phase II/III clinical trials. The per-screen cost varies substantially by therapeutic area and protocol — the cost of a screen failure in an oncology trial requiring tumor biopsy, imaging, full laboratory panel, and ECG is fundamentally different from the cost in a metabolic disease trial requiring only standard bloodwork and a vital signs assessment. Across therapeutic areas, estimates of the direct cost per failed screen range from approximately $2,000 at the low end to over $8,000 in protocol-intensive indications, and these figures do not capture the opportunity cost of coordinator time or the downstream effect on site capacity.
The indirect cost is harder to quantify but arguably more significant. Each screen failure consumes coordinator time that could have been allocated to a qualifying screen or to an enrolled patient's visit management. In sites running at high coordinator capacity utilization — which describes most high-volume research sites — screen failure volume directly competes with enrolled patient management for coordinator bandwidth. A site experiencing 60% screen failure rates is, in effect, spending nearly two-thirds of its screening-related coordinator capacity on patients who will not enroll. That capacity could otherwise support faster screening throughput or better retention management for enrolled patients.
Why Screen Failure Rates Are So Persistently High
The persistence of high screen failure rates in clinical trials is not primarily a failure of coordinator effort or site quality. It is a structural consequence of how patients are identified and referred to screening — and of a fundamental information asymmetry between the eligibility criteria in the protocol and the information that is practically available at the point of referral decision.
In a passive identification model, coordinators refer patients for formal screening when they believe, based on their clinical knowledge and a brief chart review, that the patient is likely eligible. That belief is often wrong not because the coordinator is making a careless judgment, but because the protocol criteria include elements — specific biomarker values, medication history lookbacks, organ function parameters — that are not reliably surfaced by a brief manual chart review and that require dedicated data extraction to evaluate accurately.
A coordinator assessing whether a patient meets 25 inclusion and exclusion criteria based on a chart review will miss some criteria, misinterpret others in good faith, and make temporal logic errors under time pressure. The more complex the protocol, the higher the screen failure rate from this cause — not from coordinator negligence, but from the cognitive limits of informal manual chart review against a complex eligibility specification.
The Pre-Screening Distinction
Pre-screening — applying eligibility logic to patient data before formal protocol screening begins — is the most direct lever on screen failure rates. It is worth being precise about what pre-screening means in operational terms, because the term is used in multiple contexts with different implications.
At the lowest level of sophistication, pre-screening is a coordinator conversation with the patient before scheduling the formal screening visit — covering the study requirements, visit schedule, and any immediately obvious eligibility factors. This takes 20-30 minutes of coordinator time and catches patients who self-identify as ineligible once they understand the study's requirements. It reduces screen failures but does not address the category of failures caused by EHR data elements the coordinator didn't check.
At the highest level, pre-screening is automated eligibility logic applied to structured and unstructured EHR data, evaluating the full eligibility criterion set before the coordinator is involved. This approach surfaces patients with a prior probability of eligibility based on their complete medical history, not just the information the coordinator happened to check. It catches the biomarker criteria that require pathology report extraction, the medication exclusions buried in prescription history, and the organ function criteria that require laboratory lookback — the categories of criteria most prone to informal pre-screening errors.
The screen failure rate reduction achievable by moving from informal coordinator pre-screening to systematic EHR-based pre-screening varies by therapeutic area and protocol complexity. In biomarker-selected oncology programs, where informal pre-screening routinely misses molecular criteria documented in pathology reports, the reduction can be substantial. In metabolic disease programs with primarily structured eligibility criteria and high EHR data completeness, the improvement is more modest but still measurable in per-enrolled-patient cost terms.
Protocol Criteria as a Driver of Irreducible Screen Failure Rate
Not all screen failures are reducible through better pre-screening. A meaningful fraction of failures in any trial occur on criteria that genuinely cannot be evaluated from EHR data — they require in-clinic assessments that can only be performed at the screening visit itself. ECOG performance status is the clearest example in oncology: it is a physician-assessed functional status that can be influenced by recent clinical trajectory and cannot be reliably inferred from any EHR data field. A patient who appears eligible on all coded and documented criteria may fail screening on ECOG because their recent functional decline was not yet documented at the time of matching.
Similarly, imaging-based eligibility criteria — measurable lesion requirements in oncology, specific MRI findings in CNS programs — require imaging that may not exist or may not be recent enough to use for eligibility determination. These criteria define an irreducible screen failure floor: the fraction of patients who will fail screening regardless of pre-screening quality because their eligibility status on these criteria cannot be known without the screening visit.
Understanding the composition of screen failures — what fraction are pre-screenable versus irreducibly in-clinic — is important for setting realistic pre-screening improvement targets. A screen failure rate reduction program that is evaluated against all failures will appear less effective than one evaluated against the pre-screenable fraction. Setting appropriate benchmarks requires criterion-level failure attribution, which in turn requires systematic analysis of why each screen failure occurred — a data collection discipline that most sites do not currently maintain but that is actionable with appropriate tracking infrastructure.
Site-Level Variability in Screen Failure Rates
Screen failure rates vary substantially across sites within the same multi-site trial, and that variability is informative. Sites with consistently low screen failure rates typically share identifiable characteristics: they have high EHR data completeness for the specific criteria in this protocol, they have experienced coordinators with deep familiarity with the eligibility specification, or they have been using some form of systematic pre-screening — a structured pre-screen checklist, a nurse-led eligibility review call, or an EHR query — rather than relying entirely on coordinator intuition.
Sites with consistently high screen failure rates often show one of two patterns. The first is structural: the site's patient population composition means that a high fraction of patients with the target diagnosis also have conditions that trigger exclusion criteria — a characteristic of certain patient populations at certain sites that makes the site a poor fit for the specific protocol regardless of how well pre-screening is implemented. The second is operational: the site is screening patients without adequate pre-eligibility review, typically because coordinator bandwidth is insufficient to support thorough pre-screening in addition to enrolled patient management.
Distinguishing between structural and operational screen failure causes at the site level determines the appropriate intervention. For structural mismatch, the intervention is reconsidering site selection — this site's patient population may be better suited for a different indication or a different protocol variant. For operational causes, the intervention is pre-screening infrastructure improvement — systematic EHR-based candidate list generation, structured coordinator pre-screen tools, or additional coordinator support for the screening workflow.
The Economic Case for Pre-Screening Investment
The return on investment for pre-screening infrastructure investment can be estimated with straightforward arithmetic. Take a program with 15 active sites, averaging 8 screens per month across the network, with a 55% screen failure rate. That's approximately 66 failed screens per month. At $4,000 average direct cost per failed screen, that's $264,000 per month in direct screen failure cost, plus the indirect coordinator time cost at each site.
If systematic EHR-based pre-screening reduces the failure rate by 15 percentage points — from 55% to 40% — the monthly direct screen failure cost drops to approximately $192,000. The monthly saving is $72,000. Over a 12-month enrollment period, the cumulative saving is $864,000. A pre-screening platform that costs a fraction of that amount and requires a month to deploy and integrate at each site delivers a positive return well within the first quarter of operation.
We're not saying every program will see a 15-point screen failure rate reduction — the actual improvement is highly protocol- and site-specific, and it depends on the quality of EHR data available and the accuracy of the pre-screening criteria implementation. We're saying that the economics of pre-screening investment are compelling across a wide range of realistic improvement assumptions, and that sponsors who evaluate pre-screening infrastructure on a cost-center basis rather than a cost-reduction basis are making the comparison incorrectly.
Practical Implementation Considerations
Implementing systematic pre-screening at an operational level requires attention to three practical factors that determine whether the theoretical benefit is realized in practice. First, data access — does the pre-screening system have access to the EHR data elements needed to evaluate the key criteria? Without access to molecular pathology data, organ function labs, and medication history, a pre-screening system can only address a subset of the eligibility criteria. Second, coordinator workflow integration — does the pre-screening output reach coordinators in a format that fits their existing workflow, or does it require them to check a separate system they're not accustomed to using? Third, feedback and iteration — is there a mechanism for coordinators to report back on pre-screened candidates who fail formal screening, enabling the pre-screening criteria model to be refined over time?
Programs that get all three of these implementation factors right consistently outperform programs that deploy a pre-screening tool and then evaluate it in isolation from the workflow it was meant to support. The technology is the easier part. The integration with the operational reality of site-level clinical research is where the work — and the value — actually lives.
